Verona Pharma
plc
("Verona Pharma" or the
"Company")
New clinical data
on RPL554 to be presented at the 2016 ERS International
Congress
Detailed data
from Phase 2a “add-on” trial as “LATE-BREAKING abstract”
30 August 2016, Cardiff – Verona Pharma plc (AIM: VRP.L),
the drug development company focused on first-in-class medicines to
treat respiratory diseases, today announces that it will present
three abstracts at the European Respiratory Society (ERS) 2016
International Congress in London,
UK between 3-7 September. The abstracts will cover clinical
data related to the Company’s lead drug, RPL554, a novel inhaled
dual PDE3/PDE4 inhibitor with both bronchodilator and
anti-inflammatory properties. RPL554 is currently in development as
a nebulised maintenance treatment for chronic obstructive pulmonary
disease (COPD) patients with moderate to severe disease and as a
treatment for acute exacerbations in COPD patients in a hospital or
home-care setting.
Detailed results from the Company’s Phase 2a “add-on” trial,
where RPL554 produced a statistically and clinically significant
additional bronchodilation on top of standard of care
bronchodilators in COPD patients, will be presented for the first
time in an oral presentation, by Professor Dave Singh from the Medicines Evaluation Unit,
University of Manchester, during a
late-breaker session on Monday, 5 September
2016, at 11:00 in Room C.
All three abstracts presented at ERS support Verona Pharma’s
view that RPL554 could become an important, novel and complementary
inhaled medicine for the treatment of respiratory diseases such as
COPD, asthma and cystic fibrosis. In summary, the detailed data
supports previously announced analysis of headline data which
identified:
- Profound and sustained bronchodilation in healthy volunteers,
COPD patients and asthmatics;
- Comparable bronchodilation to high dose nebulised salbutamol (a
standard of care treatment) in asthmatics with fewer systemic
effects; and
- Statistically and clinically significant improvements in lung
function when administered as “add-on” treatment to existing
standard of care bronchodilators in COPD patients.
All abstracts and details on timings can be accessed through the
ERS website: http://erscongress.org/
The title, timing and location of the abstract presentations are
as follows:
Abstract Number: |
750050 |
Authors: |
D. Singh, K.H. Abbott-Banner, K.
Newman |
Title: |
LATE-BREAKING ABSTRACT: The novel
inhaled dual PDE3/4 Inhibitor, RPL554, produces significant
additional improvements in lung function when administered on top
of existing standard of care in COPD patients |
Day/Date: |
MONDAY, September 5, 2016 |
Location: |
Room C |
Time: |
10:45 - 12:45 |
Session: |
Late-breaking topics in airways
disease |
Session Type: |
Oral Presentation |
Abstract
Number: |
851700 |
Authors: |
D. Singh, K.H. Abbott-Banner, K.
Newman |
Title: |
RPL554, an inhaled PDE3/4 inhibitor,
causes profound and sustained bronchodilation in healthy volunteers
and COPD patients |
Day/Date: |
TUESDAY, September 6, 2016 |
Location: |
T-21 |
Time: |
12:50 - 14:40 |
Session: |
Novel avenues in the treatment of
COPD |
Session Type: |
Thematic Poster Session |
Abstract Number: |
853133 |
Authors: |
L. Bjermer, J. Stewart, K.
Abbott-Banner, K. Newman |
Title: |
RPL554, an inhaled PDE3/4 inhibitor,
causes comparable bronchodilation to high dose nebulised salbutamol
in asthmatics with fewer systemic effects |
Day/Date: |
WEDNESDAY, September 7, 2016 |
Location: |
Room ICC Capital Suite 8. |
Time: |
8:30 - 10:30 |
Session: |
Novel mechanisms and treatment
modalities in asthma |
Session Type: |
Poster Discussion |
-ENDS-
About Verona Pharma
Verona Pharma plc is a UK-based clinical stage biotech company
focused on the development of innovative prescription medicines to
treat respiratory diseases with significant unmet medical needs,
such as chronic obstructive pulmonary disease (COPD), asthma and
cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase 2 trials as a nebulised maintenance treatment
for COPD patients with moderate to severe disease and possibly as a
treatment of acute exacerbations of COPD in the hospital setting.
The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and
therefore has both bronchodilator and anti-inflammatory effects,
which are essential to the improvement of patients with COPD and
asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for COPD and
asthma maintenance therapy. The Company is also exploring the
potential of the drug in different diseases, such as cystic
fibrosis, where it is in pre-clinical testing and has received a
Venture and Innovation Award from the Cystic Fibrosis Trust.
About ERS
The European Respiratory Society (ERS; www.ersnet.org) is an
international organisation that brings together physicians,
healthcare professionals, scientists and other experts working in
respiratory medicine. It is one of the leading medical
organisations in the respiratory field, with a growing membership
representing over 140 countries worldwide.
ERS’s mission is to promote lung health in order to alleviate
suffering from disease and drive standards for respiratory medicine
globally. Science, education and advocacy are at the core of
everything it does.
THE 26th ERS International Congress will take place at London’s
ExCeL Centre and will host the world's largest and most influential
meeting for respiratory physicians, scientists and allied health
professionals. The Congress Scientific programme will present the
best in science and educational sessions from distinguished
researchers from across the globe. It will cover key topics in
respiratory medicine from across the spectrum of disease areas
including TB, lung cancer, pneumonia, cystic fibrosis, COPD and
asthma amongst others.
Further information on the congress can be accessed via the
following weblink: http://erscongress.org/
For further information, please
contact:
Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, CEO |
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen
Boorer |
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Simon Conway /
Stephanie Cuthbert /
Natalie Garland-Collins |
|